LGBT Cancer Project

Therapeutic Areas: Oncology | Hematology | Musculoskeletal

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

NEW

Research Center
Additional Locations Alabama

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Arizona

NEW

Research Center
Additional Locations Arizona

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Arkansas

NEW

Research Center
Additional Locations Arkansas

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

California

NEW

Research Center
Additional Locations California

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Los Angeles California 90033

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Los Angeles California 90095

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Colorado

NEW

Research Center
Additional Locations Colorado

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Aurora Colorado 80045

A clinical trial seeking patients for a Cancer treatment research study

UPDATED

Denver Colorado 80218

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Connecticut

NEW

Research Center
Additional Locations Connecticut

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Delaware

NEW

Research Center
Additional Locations Delaware

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

District of Columbia

NEW

Research Center
Additional Locations District of Columbia

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Florida

NEW

Research Center
Additional Locations Florida

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Georgia

NEW

Research Center
Additional Locations Georgia

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Hawaii

NEW

Research Center
Additional Locations Hawaii

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Idaho

NEW

Research Center
Additional Locations Idaho

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Illinois

NEW

Research Center
Additional Locations Illinois

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Chicago Illinois 60637

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Niles Illinois 60714

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Indiana

NEW

Research Center
Additional Locations Indiana

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Indianapolis Indiana 46237

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Indianapolis Indiana 46237

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Kentucky

NEW

Research Center
Additional Locations Kentucky

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Louisville Kentucky 40207

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Louisiana

NEW

Research Center
Additional Locations Louisiana

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Maine

NEW

Research Center
Additional Locations Maine

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Maryland

NEW

Research Center
Additional Locations Maryland

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Massachusetts

NEW

Research Center
Additional Locations Massachusetts

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Boston Massachusetts 02114

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Michigan

NEW

Research Center
Additional Locations Michigan

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Minnesota

NEW

Research Center
Additional Locations Minnesota

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Mississippi

NEW

Research Center
Additional Locations Mississippi

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Missouri

NEW

Research Center
Additional Locations Missouri

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

St. Louis Missouri 63110

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Nebraska

NEW

Research Center
Additional Locations Nebraska

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Nevada

NEW

Research Center
Additional Locations Nevada

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

New Hampshire

NEW

Research Center
Additional Locations New Hampshire

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

New Jersey

NEW

Research Center
Additional Locations New Jersey

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Hackensack New Jersey 07601-1915

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

New Mexico

NEW

Research Center
Additional Locations New Mexico

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Albuquerque New Mexico 87106

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

New York

NEW

Research Center
Additional Locations New York

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Buffalo New York 14263

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

New York New York 10021

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

New York New York 10065

A clinical trial seeking patients for a Cancer treatment research study

UPDATED

New York New York 10032

Patients are needed to participate in a clinical research study of PLX51107 to evaluate Solid Tumors, Acute Myeloid Leukemia or Myelodysplastic Syndrome

UPDATED

Stony Brook New York 11794

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Stony Brook New York 11794

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

North Carolina

NEW

Research Center
Additional Locations North Carolina

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Durham North Carolina 27710

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia